Harpoon Therapeutics Inc (NASDAQ:HARP)’s share price hit a new 52-week low during trading on Wednesday . The company traded as low as $10.53 and last traded at $11.19, with a volume of 1350 shares trading hands. The stock had previously closed at $11.76.
A number of equities analysts recently commented on the company. Wedbush initiated coverage on Harpoon Therapeutics in a report on Tuesday, March 5th. They set an “outperform” rating and a $23.00 target price for the company. Svb Leerink reiterated an “outperform” rating on shares of Harpoon Therapeutics in a report on Tuesday, March 5th. Finally, Canaccord Genuity initiated coverage on Harpoon Therapeutics in a report on Tuesday, March 5th. They issued a “buy” rating and a $24.00 price objective for the company.
In other news, major shareholder Bioscience Plc Arix acquired 428,571 shares of the firm’s stock in a transaction on Tuesday, February 12th. The stock was acquired at an average price of $14.00 per share, for a total transaction of $5,999,994.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Luke Evnin acquired 250,000 shares of the firm’s stock in a transaction on Tuesday, February 12th. The stock was purchased at an average price of $14.00 per share, with a total value of $3,500,000.00. The disclosure for this purchase can be found here.
ILLEGAL ACTIVITY WARNING: This piece was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2019/03/15/harpoon-therapeutics-harp-hits-new-1-year-low-at-10-53.html.
About Harpoon Therapeutics (NASDAQ:HARP)
Harpoon Therapeutics, Inc, a clinical-stage immunotherapy company, engages in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. It is involved in developing HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer; and HPN536 for the treatment of ovarian cancer and other mesothelin expressing tumors, as well as other products targeting tumor-associated antigens for the treatment of multiple myeloma and small-cell lung cancer.
Read More: Discount Rate
Receive News & Ratings for Harpoon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harpoon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.